nach oben

ADHD Attention Deficit and Hyperactivity Disorders

Erschienen in:

07.02.2017 | Original Article

No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson’s disease in nine ADHD candidate SNPs

verfasst von: Julia M. Geissler, Marcel Romanos, Manfred Gerlach, Daniela Berg, Claudia Schulte, International Parkinson Disease Genomics Consortium members

Erschienen in: ADHD Attention Deficit and Hyperactivity Disorders | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Attention-deficit/hyperactivity disorder (ADHD) and Parkinson’s disease (PD) involve pathological changes in brain structures such as the basal ganglia, which are essential for the control of motor and cognitive behavior and impulsivity. The cause of ADHD and PD remains unknown, but there is increasing evidence that both seem to result from a complicated interplay of genetic and environmental factors affecting numerous cellular processes and brain regions. To explore the possibility of common genetic pathways within the respective pathophysiologies, nine ADHD candidate single nucleotide polymorphisms (SNPs) in seven genes were tested for association with PD in 5333 cases and 12,019 healthy controls: one variant, respectively, in the genes coding for synaptosomal-associated protein 25 k (SNAP25), the dopamine (DA) transporter (SLC6A3; DAT1), DA receptor D4 (DRD4), serotonin receptor 1B (HTR1B), tryptophan hydroxylase 2 (TPH2), the norepinephrine transporter SLC6A2 and three SNPs in cadherin 13 (CDH13). Information was extracted from a recent meta-analysis of five genome-wide association studies, in which 7,689,524 SNPs in European samples were successfully imputed. No significant association was observed after correction for multiple testing. Therefore, it is reasonable to conclude that candidate variants implicated in the pathogenesis of ADHD do not play a substantial role in PD.

Berg D, Siefker C, Becker G (2001) Echogenicity of the substantia nigra in Parkinson’s disease: its relation to clinical findings. J Neurol 248(8):684–689. doi:10.1007/s004150170114 CrossRefPubMed

Craig F, Margari F, Legrottaglie AR, Palumbi R, de Giambattista C, Margari L (2016) A review of executive function deficits in autism spectrum disorder and attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 12:1191–1202PubMedPubMedCentral

Crosiers D, Theuns J, Cras P, Van Broeckhoven C (2011) Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. J Chem Neuroanat 42(2):131–141CrossRefPubMed

Forero DA, Arboleda GH, Vasquez R, Arboleda H (2009) Candidate genes involved in neural plasticity and the risk for attention-deficit hyperactivity disorder: a meta-analysis of 8 common variants. J Psychiatry Neurosci 34:361–366PubMedPubMedCentral

Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U (2012) Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry 169:264–272CrossRefPubMed

Galvin JE (2006) Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson’s disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol 112:115–126. doi:10.1007/s00401-006-0096-2 CrossRefPubMed

Geng DY, Li YX, Zee CS (2006) Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson’s disease. Neurosurgery 58:256–261. doi:10.1227/01.NEU.0000194845.19462.7B CrossRefPubMed

Gerlach M, Romanos M (2014) Attention-deficit/hyperactivity disorder. In: Wolters E, Baumann C (eds) Parkinson disease and other movement disorders. Motor behavioural disorders and behavioural motor disorders. International Association of Parkinsonism and Related Disorders, VU University Press, Amsterdam, pp 705–727

Gibb WR, Lees AJ (1991) Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson’s disease. J Neurol Neurosurg Psychiatry 54:388–396. doi:10.1136/jnnp.54.5.388 CrossRefPubMedPubMedCentral

Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606–661CrossRefPubMed

Gizer I, Ficks C, Waldman I (2009) Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 126:51–90. doi:10.1007/s00439-009-0694-x CrossRefPubMed

Goldman JG, Aggarwal NT, Schroeder CD (2015) Mild cognitive impairment: an update in Parkinson’s disease and lessons learned from Alzheimer’s disease. Neurodegener Dis Manag 5(5):425–443CrossRefPubMedPubMedCentral

Higuchi S, Muramatsu T, Arai H, Hayashida M, Sasaki H, Trojanowski JQ (1995) Polymorphisms of dopamine receptor and transporter genes and Parkinson’s disease. J Neural Transm 10:107–113CrossRef

International Parkinson Disease Genomics C, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM et al (2011) Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 377(9766):641–649CrossRef

Jarick I, Volckmar AL, Putter C, Pechlivanis S, Nguyen TT, Dauvermann MR et al (2014) Genome-wide analysis of rare copy number variations reveals PARK2 as a candidate gene for attention-deficit/hyperactivity disorder. Mol Psychiatry 19(1):115–121CrossRefPubMed

Jiang H, Jiang Q, Feng J (2004) Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J Biol Chem 279(52):54380–54386CrossRefPubMed

Juyal RC, Das M, Punia S, Behari M, Nainwal G, Singh S, Swaminath PV, Govindappa ST, Jayaram S, Muthane UB, Thelma BK (2006) Genetic susceptibility to Parkinson’s disease among South and North Indians: I. Role of polymorphisms in dopamine receptor and transporter genes and association of DRD4 120-bp duplication marker. Neurogenetics 7:223–229. doi:10.1007/s10048-006-0048-y CrossRefPubMed

Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386(9996):896–912CrossRefPubMed

Lasky-Su J, Neale BM, Franke B, Anney RL, Zhou K, Maller JB, Vasquez AA, Chen W, Asherson P, Buitelaar J, Banaschewski T, Ebstein R, Gill M, Miranda A, Mulas F, Oades RD, Roeyers H, Rothenberger A, Sergeant J, Sonuga-Barke E, Steinhausen HC, Taylor E, Daly M, Laird M, Lange Faraone SV (2008) Genome-wide association scan of quantitative traits for attention deficit hyperactivity disorder identifies novel associations and confirms candidate gene associations. Am J Med Genet B Neuropsychiatr Genet 147B:1345–1354. doi:10.1002/ajmg.b.30867 CrossRefPubMed

Le Couteur DG, Leighton PW, McCann SJ, Pond SM (1997) Association of a polymorphism in the dopamine-transporter gene with Parkinson’s disease. Mov Disord 12:760–763. doi:10.1002/mds.870120523 CrossRefPubMed

Lesage S, Brice A (2009) Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. doi:10.1093/hmg/ddp012 PubMed

Lesch K-P, Timmesfeld N, Renner TJ, Halperin R, Röser C, Nguyen TT, Craig DW, Romanos J, Heine M, Meyer J, Freitag C, Warnke A, Romanos M, Schäfer H, Walitza S, Reif A, Stephan D, Jacob C (2008) Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies. J Neural Transm 115:1573–1585. doi:10.1007/s00702-008-0119-3 CrossRefPubMed

Mehler-Wex C, Riederer P, Gerlach M (2006) Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson’s disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res 10:167–179. doi:10.1007/BF03033354 CrossRefPubMed

Morino H, Kawarai T, Izumi Y, Kazuta T, Oda M, Komure O, Udaka F, Kameyama M, Nakamura S, Kawakami H (2000) A single nucleotide polymorphism of dopamine transporter gene is associated with Parkinson’s disease. Ann Neurol 47:528–531CrossRefPubMed

Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin U-M, Saad M, Simón-Sánchez J, Schulte C, Lesage S, Sveinbjörnsdóttir S, Ki Stefánsson, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW (2011) Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 377:641–649. doi:10.1016/S0140-6736(10)62345-8 CrossRefPubMed

Neale BM, Medland S, Ripke S, Anney RJL, Asherson P, Buitelaar J, Franke B, Gill M, Kent L, Holmans Middleton F, Thapar A, Lesch K-P, Faraone SV, Daly M, Nguyen TT, Schäfer H, Steinhausen H-C, Reif A, Renner TJ, Romanos M, Romanos J, Warnke A, Walitza S, Freitag C, Meyer J, Palmason H, Rothenberger A, Hawi Z, Sergeant J, Roeyers H, Mick E, Biederman J (2010) Case-control genome-wide association study of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 49:906–920. doi:10.1016/j.jaac.2010.06.007 CrossRefPubMedPubMedCentral

Park TW, Park YH, Kwon HJ, Lim MH (2013) Association between TPH2 gene polymorphisms and attention deficit hyperactivity disorder in Korean children. Genet Test Mol Biomarkers 17:301–306. doi:10.1089/gtmb.2012.0376 CrossRefPubMed

Philippova M, Joshi MB, Kyriakakis E, Pfaff D, Erne P, Resink TJ (2009) A guide and guard: the many faces of T-cadherin. Cell Signal 21:1035–1044. doi:10.1016/j.cellsig.2009.01.035 CrossRefPubMed

Ramirez-Zamora A, Gee L, Boyd J, Biller J (2016) Treatment of impulse control disorders in Parkinson’s disease: practical considerations and future directions. Expert Rev Neurother 16(4):389–399CrossRefPubMed

Rizo J, Südhof TC (2002) Snares and Munc18 in synaptic vesicle fusion. Nat Rev Neurosci 3:641–653. doi:10.1038/nrn898 CrossRefPubMed

Romanos M, Renner TJ, Schecklmann M, Hummel B, Roos M, von Mering C, Pauli P, Reichmann H, Warnke A, Gerlach M (2010) Structural abnormality of the substantia nigra in children with attention-deficit hyperactivity disorder. J Psychiatry Neurosci 35:55–58. doi:10.1503/jpn.090044 CrossRefPubMedPubMedCentral

Sengupta SM, Grizenko N, Thakur GA, Bellingham J, Deguzman R, Robinson S, Terstepanian M, Poloskia A, Shaheen SM, Fortier ME, Choudhry Z, Joober R (2012) Differential association between the norepinephrine transporter gene and ADHD: role of sex and subtype. J Psychiatry Neurosci 37:129–137. doi:10.1503/jpn.110073 CrossRefPubMedPubMedCentral

Shaw P, Lerch JP, Greenstein D, Sharp W, Clasen LS, Evans AC, Giedd JN, Castellanos FX, Rapoport JL (2006) Longitudinal mapping of cortical thickness and clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 63:540–549. doi:10.1001/archpsyc.63.5.540 CrossRefPubMed

Sidhu A, Wersinger C, Vernier P (2004) α-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson’s disease. FEBS Lett 565:1–5CrossRefPubMed

Spencer CA, Plagnol V, Strange A, Gardner M, Paisan-Ruiz C, Band G, Barker RA, Bellenguez C, Bhatia Blackburn H, Blackwell JM, Bramon E, Brown MA, Brown MA, Burn D, Casas JP, Chinnery PF, Clarke CE, Corvin A, Craddock N, Deloukas P, Edkins S, Evans J, Freeman C, Gray E, Hardy J, Hudson G, Hunt S, Jankowski J, Langford C, Lees AJ, Markus HS, Mathew CG, McCarthy MI, Morrison KE, Palmer CNA, Pearson JP, Peltonen L, Pirinen M, Plomin R, Potter S, Rautanen A, Sawcer SJ, Su Z, Trembath RC, Viswanathan AC, Williams NW, Morris HR, Donnelly P, Wood NW (2011) Dissection of the genetics of Parkinson’s disease identifies an additional association 5′ of SNCA and multiple associated haplotypes at 17q21. Hum Mol Genet 20:345–353. doi:10.1093/hmg/ddq469 CrossRefPubMed

Takeuchi T, Misaki A, Liang SB, Tachibana A, Hayashi N, Sonobe H, Ohtsuki Y (2000) Expression of T-cadherin (CDH13, H-Cadherin) in human brain and its characteristics as a negative growth regulator of epidermal growth factor in neuroblastoma cells. J Neurochem 74:1489–1497CrossRefPubMed

Volkmann J, Daniels C, Witt K (2010) Neuropsychiatric effects of subthalamic neurostimulation in Parkinson disease. Nat Rev Neurol 6:487–498. doi:10.1038/nrneurol.2010.111 PubMed

Walitza S, Romanos M, Warnke A, Greenhill L, Gerlach M (2014) Psychostimulants and other drugs used in the treatment of attention-deficit/hyperactivity disorder (ADHD). In: Gerlach M, Warnke A, Greenhill L (eds) Psychiatric drugs in children and adolescents. Basic pharmacology and practical applications. Springer, Wien, pp 293–333

Titel: No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson’s disease in nine ADHD candidate SNPs
verfasst von: Julia M. Geissler
Marcel Romanos
Manfred Gerlach
Daniela Berg
Claudia Schulte
International Parkinson Disease Genomics Consortium members
Publikationsdatum: 07.02.2017
Verlag: Springer Vienna
Erschienen in: ADHD Attention Deficit and Hyperactivity Disorders / Ausgabe 2/2017
Print ISSN: 1866-6116
Elektronische ISSN: 1866-6647
DOI: https://doi.org/10.1007/s12402-017-0219-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson’s disease in nine ADHD candidate SNPs

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Supporting patients with ADHD: Missed opportunities?

Assessment of effects of atomoxetine in adult patients with ADHD: consistency among three geographic regions in a response maintenance study

The use of compensatory strategies in adults with ADHD symptoms

Early maladaptive schemas in adult patients with attention deficit hyperactivity disorder

Pre-service teachers’ perceptions of sluggish cognitive tempo

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie